Search results for "LECA"

showing 10 items of 76 documents

Líquenes y hongos liquenícolas de la Serranía de Ronda (Málaga-Cádiz), sur de España

2017

As a result of a field trip organised by the Spanish Lichen Society in Serranía de Ronda, south Spain, a catalogue of 360 taxa is presented (336 lichens, 24 lichenicolous fungi). The list includes three new records for the Iberian Peninsula: Arthonia paretinaria, Micarea myriocarpa and Niesslia keissleri, 51new ones for the Autonomous Andalusian Community, and three and 81 new ones for the province of Cádiz and of Málaga, respectively. After these results, the total updated number of the province of Málaga rises to 556 lichens and lichenicolous fungi. The best represented lichen genus is Cladonia (18) with the most species, unlike Lecanora (15), Pertusaria (12), Physconia (12) and Collema (…

0106 biological sciences0301 basic medicineLichensArthoniaLecanoraNiesslia.Plant Science010603 evolutionary biology01 natural sciences03 medical and health sciencesArthoniaFongsMicareaBotanyPertusariaLíquensLichenEcology Evolution Behavior and SystematicsCollemabiologyCladonianuevas citasPhysconiaBotánicaFunginew recordsForestry030108 mycology & parasitologybiology.organism_classificationCrustose
researchProduct

The immunological implication of the new vitamin D metabolism

2018

Vitamin D is a neuro-hormone regulating calcium-phosphate homeostasis, cell proliferation, and immunomodulation. exogenous and endogenous Vitamin D is inactive, and two hydroxylations are required to produce the active hormone. The first hydroxylation is unique to the liver, while the second step occurs in kidney, brain, lung, prostate, placenta, and immune cells. Kidney-derived calcitriol regulates calcium homeostasis. active hormone produced by brain and immune cells mediates immune system response; lung calcitriol is involved in fighting respiratory tract infections; finally, prostate and placenta Vitamin D regulates cells growth and proliferation within such tissues. immune modulation b…

0301 basic medicineCalcitriolImmunologylcsh:Medicinevitamin Dmedicine.disease_causeimmunomodulationCalcitriol receptorAutoimmunity03 medical and health scienceschemistry.chemical_compound0302 clinical medicineImmune systemCYPsCYPVitamin D and neurologyImmunology and AllergyMedicineVDRCalcium metabolismReview PaperInnate immune systembusiness.industryautoimmunitylcsh:R030104 developmental biologychemistryImmunologybusinessCholecalciferol030217 neurology & neurosurgerymedicine.drugCentral European Journal of Immunology
researchProduct

NG2/CSPG4 and progranulin in the posttraumatic glial scar.

2018

Traumatic injury of the central nervous system is one of the leading causes of death and disability in young adults. Failure of regeneration is caused by autonomous neuronal obstacles and by formation of the glial scar, which is essential to seal the injury but also constitutes a barrier for regrowing axons. The scar center is highly inflammatory and populated by NG2+ glia, whereas astrocytes form the sealing border and trap regrowing axons, suggesting that the non-permissive environment of activated astrocytes and extracellular matrix components is one of the reasons for the regenerative failure. Particularly, secreted chondroitin-sulfate proteoglycans, CSPGs, of the lectican family hinder…

0301 basic medicineCentral nervous systemPerlecanCell CommunicationBiologyGlial scarExtracellular matrix03 medical and health scienceschemistry.chemical_compoundCicatrix0302 clinical medicineProgranulinsmedicineLecticanAnimalsHumansMolecular BiologyMicrogliaReceptors NotchMembrane ProteinsCell biology030104 developmental biologymedicine.anatomical_structurenervous systemchemistryChondroitin Sulfate ProteoglycansChondroitin sulfate proteoglycanBrain InjuriesImmunologybiology.proteinSynaptic signalingNeuroglia030217 neurology & neurosurgeryHeparan Sulfate ProteoglycansSignal TransductionMatrix biology : journal of the International Society for Matrix Biology
researchProduct

Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy

2021

Background & Aims There are limited data on patients with chronic HCV infection in whom combination voxilaprevir (VOX), velpatasvir (VEL), sofosbuvir (SOF) retreatment fails. Thus, we aimed to assess treatment failure and rescue treatment options in these patients. Methods Samples from 40 patients with HCV genotypes (GT) 1-4 in whom VOX/VEL/SOF retreatment failed were collected within the European Resistance Study Group. Population-based resistance analyses were conducted and clinical parameters and retreatment efficacies were evaluated retrospectively in 22 patients. Results Most VOX/VEL/SOF failure patients were infected with HCV GT3a (n = 18, 45%) or GT1a (n = 11, 28%) and had cirrhosis …

0301 basic medicineHepatitis C Virusmedicine.medical_specialtySofosbuvirVoxilaprevirPopulationresistance-associated substitutionsDirect-acting antiviralVoxilaprevir/velpatasvir/sofosbuvir.GastroenterologySettore MED/07Telaprevir03 medical and health scienceschemistry.chemical_compound0302 clinical medicineVoxilaprevir/Velpatasvir/SofosbuvirInternal medicineBoceprevirRescue therapymedicineResistance-associated substitutioneducationdirect-acting antiviralsDAAeducation.field_of_studyHepatologybusiness.industryvirus diseasesGlecaprevirDAA; HCV; Hepatitis C Virus; Voxilaprevir/Velpatasvir/Sofosbuvir; direct-acting antivirals; rescue therapy; resistance-associated substitutionsdigestive system diseasesPibrentasvirRegimen030104 developmental biologychemistryHCV030211 gastroenterology & hepatologyHepatitis C virubusinessmedicine.drugJournal of Hepatology
researchProduct

Addressing HCV Elimination Barriers in Italy: Healthcare Resource Utilization and Cost Impact Using 8 Weeks’ Glecaprevir/Pibrentasvir Therapy

2021

Introduction: In Italy, hepatitis C virus (HCV) elimination is achievable; however, barriers remain to achieving the World Health Organization's elimination targets, and have become more pronounced with the spread of COVID-19. Glecaprevir/pibrentasvir (G/P) is a direct-acting antiviral therapy for HCV, approved for 8-week treatment in patients without cirrhosis, and with compensated cirrhosis (CC). Previously, 12 weeks of therapy was recommended for patients with CC. Shortened treatment may reduce the burden on healthcare resources, allowing more patients to be treated. This study presents the benefits that 8-week vs 12-week treatment with G/P may have in Italy. Methods: A multicohort Marko…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)EliminationTreatment duration030106 microbiologyPopulationTreatment duration03 medical and health sciences0302 clinical medicineHealth careTreatment duration.Medicine030212 general & internal medicineeducationOriginal ResearchHepatitis C viruseducation.field_of_studyGlecaprevir/pibrentasvirbusiness.industryGlecaprevirPibrentasvirInfectious DiseasesItalyEmergency medicineObservational studyGlecaprevir / pibrentasvirHepatitis C virubusinessInfectious Diseases and Therapy
researchProduct

Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microa…

2016

Purpose: Erlotinib is a targeted agent commonly used in advanced non-small cell lung cancer (aNSCLC). However, drug-related skin toxicity often may affect the quality of life of cancer patients and lead to treatment discontinuation. Genetic polymorphisms in drug transporters and metabolizing enzymes play a major role in the interindividual variability in terms of efficacy and toxicity of erlotinib treatment. The aim of our study was to identify genetic determinants in adsorption, distribution, metabolism, and excretion genes influencing skin rash (SR) by the novel drug-metabolizing enzyme and transporter (DMET) microarray Affymetrix platform in aNSCLC patients. Methods: In a retrospective s…

0301 basic medicineOncologyMaleCancer ResearchLung Neoplasmsgenetic structuresMicroarrayPharmacologyToxicologySkin rash.0302 clinical medicineNon-small cell lung cancerCarcinoma Non-Small-Cell LungGenotypePharmacology (medical)Erlotinib HydrochlorideCholecalciferolOligonucleotide Array Sequence AnalysisSkin rashMiddle AgedOncologyErlotinib030220 oncology & carcinogenesisFemaleErlotinibDrug Eruptionsmedicine.drugmedicine.medical_specialtyGenotypeSingle-nucleotide polymorphismAntineoplastic AgentsPolymorphism Single Nucleotide03 medical and health sciencesErlotinib HydrochlorideInternal medicinemedicineHumansLung cancerAgedRetrospective StudiesPharmacology25-Hydroxyvitamin D3 1-alpha-HydroxylaseInflammationbusiness.industryMicroarray analysis techniquesCancerSingle nucleotide polymorphismsmedicine.diseaseSingle nucleotide polymorphism030104 developmental biologyDMETQuality of Lifebusiness
researchProduct

Vitamin D3 affects innate immune status of European sea bass (Dicentrarchus labrax L.)

2017

The effects of vitamin D3 dietary administration on certain innate immune parameters on the expression of immune-related genes in head-kidney (HK) and gut were investigated in European sea bass Dicentrarchus labrax. Vitamin D3 (vD3) was orally administered to fish in a commercial pellet food supplemented with 0 (control); 3750; 18,750; or 37,500 U kg−1. Furthermore, gut histology was considered. This study showed a modulation in the activities examined in fish fed with the addition of vD3. After just 2 weeks of administration, diet supplementation with the vitamin resulted in increased phagocytic ability, while serum peroxidase content was increased in fish fed with all experimental diets a…

0301 basic medicineVitaminmedicine.medical_specialtyfood.ingredient3PhysiologyTeleostFish farmingAquatic ScienceBiochemistry)03 medical and health scienceschemistry.chemical_compoundBass (fish)foodAquacultureInternal medicinemedicineSea bassInnate immunityInnate immune systembiologybusiness.industryGeneral Medicinebiology.organism_classificationEuropean sea bass (Dicentrarchus labrax L.)030104 developmental biologyEndocrinologychemistryImmunologyDicentrarchusCholecalciferolbusinessCholecalciferol (vitamin DFish Physiology and Biochemistry
researchProduct

Measurement of Higgs boson properties in the diphoton decay channel and a search for di-Higgs production in the gamma gamma b anti-b final state with…

2018

La búsqueda del bosón de Higgs fue la pieza central de los programas de física para los experimentos en el Gran Colisionador de Hadrones durante el Run 1 de la toma de datos. El descubrimiento de esta partícula, anunciado el 4 de julio de 2012 por las colaboraciones de ATLAS y CMS, representó un hito a la hora de comprender el mecanismo de ruptura de simetría electrodébil, por el cual las partículas fundamentales adquieren masa. Ahora es esencial que el bosón de Higgs sea ampliamente estudiado. Las mediciones precisas de sus propiedades confirmarán su naturaleza y cualquier desviación de la predicción del Modelo Estándar representará un signo claro de nueva física. Esta tesis presenta dos a…

:FÍSICA [UNESCO]Higgs bosondi-HiggsCERNUNESCO::FÍSICAphotonsLHCATLASTileCal
researchProduct

Analysis of the Tile-Cal (ATLAS) prototypes and study of Higgs production in LHC

2000

Test de los prototipos del calorímetro hadrónico del detector ATLAS del CERN. Búsqueda del Bosón de Higgs desintegrándose a dos quarks tops, dentro del modelo MSSM en el detector ATLAS.

:FÍSICA::Física de altas energías [UNESCO]Physics::Instrumentation and Detectorstilecal:FÍSICA [UNESCO]High Energy Physics::LatticeHigh Energy Physics::PhenomenologyUNESCO::FÍSICA::Física de altas energíasUNESCO::FÍSICAHigh Energy Physics::ExperimentatlasLHCbosón de Higgs
researchProduct

Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection

2019

Background and aims Chronic hepatitis C virus (HCV) infection increases the risk of incident chronic kidney disease (CKD) and progression to end-stage renal disease (ESRD). Previously available direct-acting antiviral regimens are not approved for patients with advanced CKD across all HCV genotypes. Methods EXPEDITION-5 is a phase 3 study to evaluate efficacy and safety of the fixed-dose combination of glecaprevir and pibrentasvir (G/P) for chronic HCV infection (genotype 1 through 6) in adults without cirrhosis or with compensated cirrhosis and with stage 3b, 4 or 5 CKD. Patients received approved duration of G/P according to HCV genotype, cirrhosis status and prior HCV treatment experienc…

AdultCyclopropaneshepatitis C virusmedicine.medical_specialtyAminoisobutyric AcidsPyrrolidinesCirrhosisProlineLactams Macrocyclicmedicine.medical_treatmentAntiviral Agents03 medical and health sciences0302 clinical medicineLeucineQuinoxalinesInternal medicineGenotypeHumansMedicineAdverse effectDialysisSulfonamidesdirect-acting antiviralpangenotypicHepatologychronic kidney disease; cirrhosis; direct-acting antiviral; hepatitis C virus; pangenotypicbusiness.industrycirrhosisGlecaprevirHepatitis C Chronicmedicine.diseasePibrentasvirDrug Combinations030220 oncology & carcinogenesisBronchitisBenzimidazoles030211 gastroenterology & hepatologybusinesschronic kidney diseaseKidney disease
researchProduct